Javier Olazarán, MD, PhD, Gregorio Marañón Hospital, Madrid, Spain, discusses the safety of plasma exchange as a treatment for Alzheimer’s disease (AD). In the AMBAR study (NCT01561053), which evaluated plasma exchange with albumin replacement in mild/moderate Alzheimer’s disease (AD), the treatment was well-tolerated. Dr Olazarán highlights the encouraging findings from the AMBAR trial and believes plasma exchange will have an important role in the early treatment of AD patients in the near future. This interview took place during the European Academy of Neurology 2021 congress.
Personal compensation, serving on a scientific advisory board or as speaker from: Zambon, Grifols, Nutricia, and Bial.
Research support from: Nutricia.